CAR T cell therapy for multiple myeloma: where are we now and where are we headed?

Leuk Lymphoma. 2018 Sep;59(9):2056-2067. doi: 10.1080/10428194.2017.1393668. Epub 2017 Nov 6.


While recent progress has been made in the management of multiple myeloma, it remains a highly fatal malignancy especially among patients with relapsed-refractory disease. Immunotherapy with adoptive T cells targeting myeloma-associated antigens are at various stages of development and have brought about a new hope for cure. This is a review on the emerging field of adoptively transferred engineered T cell based approaches, with an in-depth focus on chimeric antigen receptors (CAR) targeting multiple myeloma. The recent results from CAR T cells targeting B cell maturation antigen are encouraging but eventual resistance to the CAR T cell therapies remain problematic. With newer approaches in therapies for multiple myeloma, the role of transplantation is evolved to form a platform for T cell therapies.

Keywords: BCMA; CAR; Multiple myeloma; TCR; chimeric antigen receptors; hematopoietic cell transplantation; immunotherapy.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Clinical Trials as Topic / methods
  • Humans
  • Immunotherapy, Adoptive / methods*
  • Immunotherapy, Adoptive / trends
  • Models, Immunological
  • Multiple Myeloma / immunology
  • Multiple Myeloma / therapy*
  • Receptors, Antigen, T-Cell / immunology*
  • Receptors, Chimeric Antigen / immunology*
  • Recombinant Fusion Proteins / immunology
  • T-Lymphocytes / immunology


  • CTL019 chimeric antigen receptor
  • Receptors, Antigen, T-Cell
  • Receptors, Chimeric Antigen
  • Recombinant Fusion Proteins